The client was a passive stakeholder in a bulk drug-manufacturing organisation and had performed poorly in the past. Regular investments of capital had yielded poor returns. The bulk drug manufacturer developed a revival plan and asked for additional investment by the partner, i.e. our client. The top management requested UC Strategy to evaluate the revival plan and to express an opinion on the feasibility of additional investment to support the revival plan.
To evaluate the feasibility of the investment opportunity, UC Strategy adopted the following approach:
- Conducted a plant visit and assessed the manufacturing capabilities
- Conducted secondary and primary research with respect to the following
- Analysed sales trends of formulation products based on the bulk drugs manufactured – Growth/ key customers
- Analysed imports/exports of the products (derivatives) and their bases
- Analysed price trend and impact of regulation on prices
- Assessed competition – capability, entry barriers, future plans etc.
- Established customer concerns, while dealing with the bulk drug manufacturer
- Reviewed the revival plan – assumptions, projections and financials based on detailed understanding of the market
- UC Strategy mapped each product – projections vs. market realities
- Independently defined scenario and indicative financials – Turnover/ Profit Before Tax/ Working Capital.
The client received an objective opinion on the feasibility of additional investment